A Single-Cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid Leukemia
The DOI matches its Crossref record.
Abstract
Response heterogeneity to targeted therapies is a major barrier to achieving optimal outcomes in a broad range of myeloproliferative neoplasms (MPN) with druggable oncogenes. This remains the case in chronic myeloid leukemia (CML) where pharmacologic targeting of the causative BCR-ABL1 kinase with tyrosine kinase inhibitors (TKI) elicits highly heterogeneous responses. The reasons why some patients enjoy deep molecular responses while others progress to blast crisis (BC) remain unknown. CML is an ideal model to study primary drug resistance since the disease is defined and driven by BCR-ABL1, treated with potent ABL1 inhibitors, and molecular response monitoring is standard. To characterize the cellular and molecular features of primary TKI resistance, we performed single-cell multi-omics (scRNA-seq and CyTOF) and mutational analysis of pretreatment chronic phase (CP) bone marrow (BM) mononuclear cells (MNC) from three prognostic Groups: patients with major molecular responses (MMR) to first-line imatinib (IM) (Group A, n=8), sub-optimal responses to IM but favorable responses to 2nd/3rd-line TKIs (Group B, n=9); and pan-TKI resistance with eventual BC progression (Group C, n=6). We generated a single-cell atlas of 163,146 MNCs, which allowed us to identify 8 statistically significant features in pretreatment BM correlating with either IM sensitivity (MMR) or increasing resistance (Figure, top panel). Next, using an unbiased machine-learning approach, we identified leukemia stem cell (LSC) and NK cell gene expression (GE) profiles predicting IM response with >80% accuracy. To better understand the functional implications of these GE signatures, we further characterized the LSC and NK cell populations computationally and experimentally. To determine the contribution of LSC fate decisions, we employed the SCENIC algorithm to identify differential LSC regulon activity between normal BM and Groups A-C. Compared to normal BM, we found an increase in the activity of a canonical erythroid-specifying regulon (TAL1/KLF1/GATA1) in Group A LSCs, which diminished with increasing TKI resistance. Both in vitroand in vivo readouts supported the functional activity of the erythroid regulon, observable as a marked (6.3-fold in Group A vs 1.09-fold in Group C) erythroid over myeloid bias in colony forming assays, and erythroid progenitor (ERP) expansion in Group A vs C BM (p<0.05) respectively. Importantly, ERPs demonstrated exquisite TKI sensitivity compared to myeloid progenitors (p<0.001). The LSC features were lost with progressive resistance, and in patients who transformed, MYC- and IRF1-driven inflammatory regulons became evident. We next performed de novo clustering of 8,617 NK cells, and observed a 56-fold expansion (p<0.01) of a normally rare subset of hyperfunctional adaptive NK cells in Group A patients that diminished with progressive resistance. We also characterized signaling interactions between stem and progenitor cell (SPC) ligands and NK cell receptors. We found that Group A NK-SPC interactions were notable for enrichment and depletion of multiple activating and inhibitory interactions respectively. In contrast, comparing Group C vs A NK-SPC interactions, we found a striking upregulation of a key inhibitory interaction between NKG2A and HLA-E. We next assessed the interplay between genetic mutations [copy number and single nucleotide variants (CNV/SNV)] and patient-specific cluster expansions. We found that while CNV-driven clonal expansion within CML hierarchies is a marker for IM resistance, the commonest recurrent mutations in CML, including ASXL1, TET2, and SETD1B, were not associated with an increased risk of BC. Finally, and as a step toward developing clinical biomarkers, we validated our scRNA-seq findings with a custom antibody set by CyTOF and conventional flow cytometry, and found that they faithfully replicated the cell abundance gradients and GE patterns uncovered by our single cell atlas. In summary, we describe a comprehensive multi-modal analysis of the genetic, cellular and molecular features of primary TKI resistance in CML, and provide novel insights into the complex interactions between LSCs, immune cells, inflammation, and genetic mutations contributing to response heterogeneity (Figure, bottom panel). We envisage that our findings may be relevant to understanding primary resistance to targeted therapies in other MPNs. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a recent study suggested that erythroid transcription factors are a marker of good response to TKI treatment in CML patients, further supporting the role of this pathway in modifying TKI sensitivity.”
From Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia (2024) · cites this paper as [47]
Citations
Cited by
Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
Ou, X., Gao, G., Habaz, I. A., & Wang, Y. (2024) · MedComm · doi:10.1002/mco2.694 · Cited by 115
Emerging clinical applications of single-cell RNA sequencing in oncology
Boxer, E., Feigin, N., Tschernichovsky, R., Darnell, N. G., Greenwald, A., Hoefflin, R., Kovarsky, D., Simkin, D., Turgeman, S., Zhang, L., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01003-3 · Cited by 60
“Immune modulation has been shown to have a role in resistance to targeted therapies across multiple cancer types 70–72 .”
Huuhtanen, J., Awad, S. A., Theodoropoulos, J., Forstén, S., Warfvinge, R., Dufva, O., Bouhlal, J., Dhapola, P., Duàn, H., Laajala, E., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02074-w · Cited by 62
Adnan Awad, S., Dufva, O., Klievink, J., Karjalainen, E., Ianevski, A., Pietarinen, P., Kim, D., Potdar, S., Wolf, M., Lotfi, K., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101521 · Cited by 14
Dawson, A., Zarou, M. M., Prasad, B., Bittencourt‐Silvestre, J., Zerbst, D., Himonas, E., Hsieh, Y.-C., van Loon, I., Blanco, G. R., Ianniciello, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45471-0 · Cited by 15
Self-citation
Metadata
- Authors
- Krishnan, V., Schmidt, F., Nawaz, Z., Lee, K. L., Nori Venkatesh, P., Makheja, M., Chan, Z. E., Yu, M., Arul Rayan, N., Gek Liang Lim, M., Cheung, A., Bari, S., Ouyang, J., Rackham, O., Tan, T. Z., Hwang, W. Y., Chuah, C., Prabhakar, S., & Ong, S. T.
- Affiliations
- Duke-NUS Medical School (SG)
- Genome Institute of Singapore (SG)
- 2Genome Institute of Singapore, Singapore, Singapore
- Singapore General Hospital (SG)
- National Cancer Centre Singapore (SG)
- National University of Singapore (SG)
- Cancer Science Institute of Singapore (SG)
- 8Department of Hematology, Singapore General Hospital, Singapore, Singapore
- Duke University (US)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2022-11-15
- Volume
- 140
- Issue
- Supplement 1
- Pages
- 792-794
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W4310163208
- Cited by
- 15
- References
- 0
- Citations by year
- 2025: 5 · 2024: 8 · 2023: 2
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- chronic myeloid leukemia, imatinib resistance, tyrosine kinase inhibitors, BCR-ABL1, leukemia stem cells, natural killer cells, single-cell atlas, bone marrow mononuclear cells, blast crisis, heterogeneous reactions, prognostic factors, single-cell multi-omics, SCENIC
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Single-Cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid Leukemia. https://app.cochat.ai/papers/10.1182/blood-2022-165758
- The paper
- Krishnan, V., Schmidt, F., Nawaz, Z., Lee, K. L., Nori Venkatesh, P., Makheja, M., Chan, Z. E., Yu, M., Arul Rayan, N., Gek Liang Lim, M., Cheung, A., Bari, S., Ouyang, J., Rackham, O., Tan, T. Z., Hwang, W. Y., Chuah, C., Prabhakar, S., & Ong, S. T. (2022). A Single-Cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid Leukemia. Blood. https://doi.org/10.1182/blood-2022-165758
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.